无症状表型轻度肥厚型心肌病的自然史:SHaRe注册研究
该研究基于SHaRe注册,纳入2500例表型轻度HCM患者(平均年龄43岁,31%女性),随访平均7±6年,21%发生MACE。症状进展及年龄、BMI、左房径、左室壁厚度、LVOT压差和LGE与MACE风险相关。左房径和左室壁厚度的年增长速率可预测AF、HF和MVA风险。
要点
- 表型轻度HCM患者中期随访约21%发生MACE。
- 随访中出现症状进展者MACE风险增加2.79倍。
- 左房径和左室壁厚度年增长速率可预测AF、HF和MVA。
核心结论
- 约21%的表型轻度HCM患者在中位随访期间发生MACE,年龄、症状发生及左房径、左室肥厚、LVOT压差增加与MACE相关。
研究设计与样本
- 基于Sarcomeric Human Cardiomyopathy Registry的前瞻性队列研究,纳入2500例表型轻度HCM患者,平均随访7±6年。
主要发现
- 534例(21%)发生MACE,包括289例AF、69例MVA和193例HF。
- 随访中从NYHA I级进展至≥II级症状者(585例,23%)发生MACE的风险为2.79倍(95%CI:2.30-3.39倍)。
- 基线年龄(每增加10岁,HR:1.24;95%CI:1.17-1.32)、BMI(每增加5 kg/m²,HR:1.10;95%CI:1.01-1.21)、左房径(每增加5 mm,HR:1.16;95%CI:1.09-1.25)、左室最大壁厚(每增加5 mm,HR:1.27;95%CI:1.10-1.46)和LVOT压差(每增加15 mmHg,HR:1.08;95%CI:1.05-1.12)与MACE风险升高相关。
- 左室LGE存在与MACE风险增加36%(95%CI:5%-76%)相关。
- 随访中左房径每增加0.5 mm/年,AF风险HR:2.24(95%CI:1.69-2.97),HF风险HR:2.22(95%CI:1.62-3.04);左室壁厚度每增加0.5 mm/年,MVA风险HR:1.92(95%CI:1.38-2.69)。
临床怎么用
- 对表型轻度HCM患者应监测症状发生及左房径、左室壁厚度、LVOT压差的动态变化。
- 年龄、BMI、左房径、左室壁厚度、LVOT压差和LGE可帮助识别MACE高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with phenotypically mild hypertrophic cardiomyopathy (HCM) do not require symptom management, but may be at an earlier stage in the disease course, with potential to benefit from disease-modifying therapies. However, little is known about the natural history and predictors of major adverse cardiovascular events (MACE). OBJECTIVES: Using the Sarcomeric Human Cardiomyopathy Registry, we identified predictors of incident MACE and characterized disease progression in phenotypically mild HCM. METHODS: Phenotypically mild HCM was defined as: having shorter disease duration (<10 years since diagnosis or age ≤30 years), no previous MACE, being NYHA functional class I, and having a left ventricular (LV) maximal wall thickness (MWT) <25 mm. These individuals were followed prospectively for the development of symptoms or MACE: atrial fibrillation (AF), malignant ventricular arrhythmia (MVA) (sudden cardiac death, resuscitated arrest, or appropriate defibrillator therapy), heart failure (HF) (cardiac transplantation, LV assist device implantation, LV ejection fraction <35%, or NYHA functional class III or IV symptoms), stroke, or all-cause mortality. Cox regression identified MACE predictors. Linear and latent class mixed models characterized LV remodeling trajectories and risk clusters. RESULTS: Of 2,500 participants with phenotypically mild HCM (mean age 43 years, 31% women) followed for a mean duration of 7 ± 6 years, 534 (21%) developed MACE, including 289 with AF, 69 with MVA, and 193 with HF. Individuals who progressed from NYHA functional class I to ≥ II symptoms during follow-up (n = 585, 23%) were 2.79 times (95% CI: 2.30-3.39 times) more likely to experience MACE. Age at baseline (HR: 1.24; 95% CI: 1.17-1.32 per 10-year increase), body mass index (HR: 1.10; 95% CI: 1.01-1.21 per 5-kg/m2 increase), left atrial (LA) diameter (HR: 1.16; 95% CI: 1.09-1.25 per 5-mm increase), LV MWT (HR: 1.27; 95% CI: 1.10-1.46 per 5-mm increase), and LV outflow tract (LVOT) gradient (HR: 1.08; 95% CI: 1.05-1.12 per 15-mm Hg increase) associated with higher MACE rates. LV late gadolinium enhancement presence was associated with 36% (95% CI: 5%-76%) higher hazard of MACE. Remodeling trajectories during follow-up predicted risk with each 0.5 mm/year steeper increase in LA diameter associating with doubled AF (HR: 2.24; 95% CI: 1.69-2.97) and HF rates (HR: 2.22; 95% CI: 1.62-3.04) and each 0.5 mm/year steeper LV MWT increase associating with doubled MVA rates (HR: 1.92; 95% CI: 1.38-2.69). Higher sustained values and/or steeper increases in LA diameter, LV MWT, or LVOT gradient associated with the highest MACE rates. CONCLUSIONS: Approximately 21% of patients with phenotypically mild HCM developed MACE over medium-term follow-up. Older age, symptoms development, and increasing LA diameter, LV hypertrophy, or LVOT gradient associated with MACE, particularly in instances of steeper rate of change. These findings can guide management strategies and inform future studies of disease-modifying therapies.
引用
- Topriceanu CC, Balakrishnan ID, Vissing CR, et al. Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry. J Am Coll Cardiol. 2026. PMID: 42417692. doi:10.1016/j.jacc.2026.03.176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。